PENCOED, Wales, Oct. 23, 2019 /PRNewswire/ -- ReNeuron Group
plc (AIM: RENE), a UK-based global leader in the development
of cell-based therapeutics, is pleased to announce that new data
relating to its CTX stem cell platform will be presented today at
the 27th Annual Congress of the European Society of Gene
and Cell Therapy (ESGCT), a leading scientific conference
taking place this week in Barcelona,
Spain.
Dr. Steve Pells, Principal Investigator at ReNeuron, will
present new data showing the phenotypic stability and scalability
of a mesenchymal stem cell line derived from the Company's
proprietary, conditionally immortalized, human neural stem cell
line (CTX) following re-programming to a pluripotent
state.
The Company has previously presented data demonstrating that its
CTX stem cell line, currently undergoing clinical evaluation for
the treatment of stroke disability, can be successfully and rapidly
re-programmed to an embryonic stem cell-like state enabling
differentiation into any cell type. In essence, this means that the
Company is able to take its neural stem cells back to being stem
cells that can be made to develop into any other type of stem cell
including bone, nerve, muscle and skin.
The new data being presented today show for the first time that
these CTX-iPSCs (induced pluripotent stem cells) can indeed be
differentiated along different cell lineages to generate, for
example, mesenchymal stem cell lines. Further, the
mesenchymal stem cell lines generated can be grown at scale by
virtue of the Company's conditional immortalization technology,
enabling the efficient production of clinical-grade cell therapy
candidates.
These results are particularly encouraging as they demonstrate
that CTX, a well-characterized, clinical-grade neural stem cell
line, could be used to produce new conditionally immortalized
allogeneic (i.e. non-donor-specific) cell lines from any of the
three primary germ cell layers which form during embryonic
development. ReNeuron is currently exploring the potential to
develop further new allogeneic cell lines as potential therapeutic
agents in diseases of unmet medical need for subsequent licensing
to third parties.
Further information about the conference may be found at:
https://www.esgct.eu/congress/barcelona-2019.aspx
"The data we are presenting at the ESGCT Annual Congress
represent a significant advance in the use of cell re-programming
to generate new allogeneic cell lines as potential therapeutic
candidates," commented Dr. Randolph
Corteling, Head of Research at ReNeuron. "Importantly, the
maintenance of the immortalization technology within these new cell
lines may allow for the scaled production of 'off the shelf'
allogeneic stem cells, such as haematopoietic stem cells as a
potential alternative approach to those cancer immunotherapies
currently in development that rely on the use of the patient's own
T-cells."
About ReNeuron
ReNeuron is a global leader in
cell-based therapeutics, harnessing its unique stem cell
technologies to develop 'off the shelf' stem cell treatments,
without the need for immunosuppressive drugs. The Company's
lead clinical-stage candidates are in development for the
blindness-causing disease, retinitis pigmentosa, and for disability
as a result of stroke. ReNeuron is also advancing its
proprietary exosome technology platform as a potential delivery
system for drugs that would otherwise be unable to reach their site
of action. ReNeuron's shares are traded on the London AIM
market under the symbol RENE.L. For further information visit
www.reneuron.com.
ENQUIRIES:
ReNeuron
|
+44 (0)20 3819
8400
|
Olav Hellebø, Chief
Executive Officer
|
|
Michael Hunt, Chief
Financial Officer
|
|
Buchanan
(UK)
|
+44 (0) 20 7466
5000
|
Mark Court, Tilly
Abraham
|
|
Argot Partners
(US)
Stephanie Marks,
Claudia Styslinger
Stifel Nicolaus
Europe Limited
|
+1 212 600
1902
+44 (0)
20 7710 7600
|
Jonathan Senior,
Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
|
|
N+1
Singer
|
+44 (0) 20 7496
3000
|
Aubrey Powell, James
Moat, Mia Gardner
(Joint
Broker)
|
|
View original
content:http://www.prnewswire.com/news-releases/reneuron-presents-positive-data-at-the-27th-annual-congress-of-the-european-society-of-gene-and-cell-therapy-on-lead-cell-line-300944420.html
SOURCE ReNeuron Group plc